Advertisement
A or ALC or SYK
Which Stock Would AI Choose? Agilent Technologies (A) vs. Alcon (ALC) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Agilent Technologies has shown the strongest recent momentum, with accelerating revenue growth, margin expansion, and multiple analyst upgrades over recent weeks.
- Alcon is growing sales steadily but faces tariff pressure, competitive headwinds, and a large one-time write-off that has weighed on earnings and sentiment.
- Stryker is recovering from a first-quarter cybersecurity disruption and delivered a strong second quarter, yet its shares remain well below their 52-week high.
- The three names span distinct healthcare niches: laboratory instrumentation (A), eye care (ALC), and medical technology and orthopaedics (SYK).
- Valuation, trend consistency, and catalyst visibility diverge meaningfully, creating distinct trade-offs for different investor profiles.
Introduction
Investors scanning the healthcare landscape often encounter three superficially similar yet operationally distinct companies: A (Agilent Technologies), ALC (Alcon), and SYK (Stryker). Agilent supplies analytical instruments and consumables to life sciences and diagnostics labs; Alcon is a global leader in eye care devices and contact lenses; and Stryker manufactures surgical equipment, implants, and robotic systems. This stock comparison is relevant to traders seeking relative-performance signals and to long-term investors weighing growth durability, sector exposure, and risk. Understanding how each name has behaved in recent market activity helps clarify where momentum, stability, and catalysts currently align.
A Overview and Recent Performance
A (Agilent Technologies) provides instruments, software, and consumables across life sciences, diagnostics, and applied chemical markets. In its most recent quarterly report, the company posted revenue of roughly $1.88 billion with core growth exceeding guidance, while earnings per share (EPS, or profit allocated to each outstanding share) rose about 14% excluding one-time tariff refunds. Operating margin expanded, and management highlighted strength in pharmaceutical demand, advanced materials, and China.
Recent weeks have brought a series of positive analyst actions, including an upgrade to Buy and a new Outperform coverage initiation, reflecting improving end-market conditions. Agilent's "Ignite" operating program and a growing instrument replacement cycle have supported a book-to-bill ratio above one for ten consecutive quarters, signaling sustained demand. This favorable mix of momentum and fundamentals has helped the stock outperform many healthcare peers, although its valuation remains richer than some value-oriented alternatives.
ALC Overview and Recent Performance
ALC (Alcon) is a leading eye care company operating across two segments: surgical (including intraocular lenses and cataract equipment) and vision care (contact lenses and ocular health). Sales have grown at a mid-single-digit pace on a constant-currency basis, supported by new product launches such as the Unity surgical platform and the Tryptyr dry-eye treatment. However, earnings have been pressured by import tariffs, competitive intensity, and a large non-cash charge tied to the discontinuation of certain intraocular lens programs.
Recent market activity has reflected this mixed picture. The stock has traded lower over the trailing year, and analysts have modestly trimmed price targets even as some maintain Buy ratings. Alcon's "razor-and-blade" model, with recurring consumable revenue tied to an installed equipment base, offers long-term appeal, but near-term sentiment has been constrained by tariff exposure and slower procedural volume growth in key markets.
SYK Overview and Recent Performance
SYK (Stryker) is a diversified medical technology company spanning orthopaedics, surgical equipment, neurotechnology, and robotics. A first-quarter cybersecurity incident disrupted production and shipments, but the second quarter showed a sharp recovery, with organic sales growth near 9% and adjusted EPS rising close to 18% year over year. Record Mako robotic system installations and broad demand supported the rebound, while adjusted operating margin improved.
Despite stronger results, the shares have lagged, trading well below their 52-week high and down year to date. A planned CEO transition and lingering execution considerations, including vascular supply disruptions, have kept sentiment cautious. Stryker trades at a forward earnings multiple below its own five-year median, which some investors interpret as a more reasonable entry point relative to its historical premium.
Trending AI Robots
For traders seeking a systematic edge across names like these, Tickeron's Trending AI Robots page curates a selection of AI trading bots chosen for their fit with current market conditions. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and watchlist. Because no single approach suits every environment, only the bots demonstrating the most relevant statistics and recent consistency earn a place in this curated section. Exploring the page can help investors evaluate how algorithmic strategies are currently positioned across momentum, trend-following, and other systematic approaches.
Head-to-Head Comparison
The clearest contrast is sector exposure and growth character. A is tied to laboratory capital spending and pharmaceutical research cycles, giving it cyclical sensitivity but strong current catalysts. ALC relies on elective eye procedures and consumer lens demand, offering recurring revenue but facing tariff and competitive headwinds. SYK blends elective surgical procedures with capital equipment and robotics, delivering scale and diversification.
On momentum, A has been the standout, with improving fundamentals and analyst upgrades reinforcing an uptrend. SYK shows improving operations but weaker share-price trend consistency following its cyber disruption and leadership transition. ALC sits between the two, with solid sales growth offset by margin pressure and a softer relative performance. Valuation sensitivity also differs: Agilent's premium reflects its momentum, Stryker's discount reflects recovery uncertainty, and Alcon's multiple reflects its recurring-revenue model despite near-term earnings noise.
Tickeron AI Verdict
Based on observable trend consistency, catalyst visibility, and relative positioning, Tickeron's AI would likely favor A (Agilent Technologies) in the current environment. The company combines accelerating core growth, expanding margins, sustained order strength, and positive analyst momentum, factors that algorithmic models typically weight favorably. SYK presents an improving but less certain setup given its cyber-recovery transition, while ALC offers longer-term appeal that may not yet be reflected in trend signals. This assessment is probabilistic rather than definitive, reflecting the balance of current data rather than a forecast of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for A turns positive, indicating new upward trend
A saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 61 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +4.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where A advanced for three days, in 188 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 141 of 209 cases where A Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for A moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 21 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for A turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 28 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where A declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
A broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. A’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.658) is normal, around the industry mean (66.046). P/E Ratio (34.163) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (1.447) is also within normal values, averaging (3.473). Dividend Yield (0.006) settles around the average of (0.002) among similar stocks. P/S Ratio (5.910) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. A’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
ALC in upward trend: price rose above 50-day moving average on October 22, 2026
ALC moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend. In 23 of 33 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ALC as a result. In 61 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for ALC just turned positive on October 09, 2026. Looking at past instances where ALC's MACD turned positive, the stock continued to rise in 28 of 53 cases over the following month. The odds of a continued upward trend are 53%.
Following a +5.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALC advanced for three days, in 181 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ALC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALC entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. ALC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.581) is normal, around the industry mean (4.961). P/E Ratio (53.508) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (1.165) is also within normal values, averaging (4.143). Dividend Yield (0.015) settles around the average of (0.005) among similar stocks. P/S Ratio (2.996) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
SYK in upward trend: price rose above 50-day moving average on October 20, 2026
SYK moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 24 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 57%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on SYK as a result. In 48 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for SYK just turned positive on September 28, 2026. Looking at past instances where SYK's MACD turned positive, the stock continued to rise in 23 of 44 cases over the following month. The odds of a continued upward trend are 52%.
Following a +3.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in 171 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
SYK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SYK entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.910) is normal, around the industry mean (2.874). P/E Ratio (31.560) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.052). Dividend Yield (0.011) settles around the average of (0.009) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
A | ALC | SYK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 15 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 69 Overvalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 91 | 100 | 76 | |
SMR RATING 1..100 | 45 | 88 | 52 | |
PRICE GROWTH RATING 1..100 | 5 | 56 | 56 | |
P/E GROWTH RATING 1..100 | 36 | 10 | 83 | |
SEASONALITY SCORE 1..100 | 85 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (24) in the Biotechnology industry is somewhat better than the same rating for ALC (69) in the Hospital Or Nursing Management industry, and is somewhat better than the same rating for SYK (76) in the Medical Specialties industry. This means that A's stock grew somewhat faster than ALC’s and somewhat faster than SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (76) in the Medical Specialties industry is in the same range as A (91) in the Biotechnology industry, and is in the same range as ALC (100) in the Hospital Or Nursing Management industry. This means that SYK's stock grew similarly to A’s and similarly to ALC’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is in the same range as SYK (52) in the Medical Specialties industry, and is somewhat better than the same rating for ALC (88) in the Hospital Or Nursing Management industry. This means that A's stock grew similarly to SYK’s and somewhat faster than ALC’s over the last 12 months.
A's Price Growth Rating (5) in the Biotechnology industry is somewhat better than the same rating for SYK (56) in the Medical Specialties industry, and is somewhat better than the same rating for ALC (56) in the Hospital Or Nursing Management industry. This means that A's stock grew somewhat faster than SYK’s and somewhat faster than ALC’s over the last 12 months.
ALC's P/E Growth Rating (10) in the Hospital Or Nursing Management industry is in the same range as A (36) in the Biotechnology industry, and is significantly better than the same rating for SYK (83) in the Medical Specialties industry. This means that ALC's stock grew similarly to A’s and significantly faster than SYK’s over the last 12 months.
| A | ALC | SYK | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 75% | 2 days ago 71% | 2 days ago 58% |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 49% | 2 days ago 50% |
| Momentum ODDS (%) | 2 days ago 70% | 2 days ago 67% | 2 days ago 53% |
| MACD ODDS (%) | 2 days ago 62% | 2 days ago 53% | 2 days ago 52% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 58% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 63% | 2 days ago 57% | 2 days ago 50% |
| Advances ODDS (%) | 3 days ago 62% | 9 days ago 57% | 4 days ago 56% |
| Declines ODDS (%) | 5 days ago 63% | 5 days ago 56% | 10 days ago 52% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 66% | 2 days ago 70% |
| Aroon ODDS (%) | 2 days ago 67% | 2 days ago 58% | 2 days ago 45% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green while ALC’s FA Score has 1 green FA rating(s), and SYK’s FA Score reflects 0 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- ALC’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 3 TA indicator(s) are bullish while ALC’s TA Score has 4 bullish TA indicator(s), and SYK’s TA Score reflects 4 bullish TA indicator(s).
- A’s TA Score: 3 bullish, 5 bearish.
- ALC’s TA Score: 4 bullish, 5 bearish.
- SYK’s TA Score: 4 bullish, 5 bearish.
Price Growth
A (@Medical Specialties) experienced а -0.95% price change this week, while ALC (@Pharmaceuticals: Other) price change was +6.08% , and SYK (@Medical/Nursing Services) price fluctuated +4.72% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.54%. For the same industry, the average monthly price growth was -5.91%, and the average quarterly price growth was +42.02%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.86%. For the same industry, the average monthly price growth was -3.31%, and the average quarterly price growth was +7.53%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.53%. For the same industry, the average monthly price growth was -9.75%, and the average quarterly price growth was -10.71%.
Reported Earning Dates
A is expected to report earnings on Nov 23, 2026.
ALC is expected to report earnings on Nov 10, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical Specialties (+1.54% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (+2.86% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-0.53% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with BRKR. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then BRKR could also see price increases.
ALC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALC has been loosely correlated with SYK. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALC jumps, then SYK could also see price increases.